What is the price target for ALXO stock?
13 analysts have analysed ALXO and the average price target is 4.69 USD. This implies a price increase of 180.96% is expected in the next year compared to the current price of 1.67.
ALX ONCOLOGY HOLDINGS INC (ALXO) Forecast, Price Target & Analyst Ratings
NASDAQ:ALXO • US00166B1052
Current stock price
1.67 USD
+0.08 (+5.03%)
At close:
1.6697 USD
0 (-0.02%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ALX ONCOLOGY HOLDINGS INC (ALXO).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 7, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.22
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$4.69
Upside
+ 180.96%
From current price of $1.67 to mean target of $4.69, Based on 13 analyst forecasts
Low
$4.04
Median
$4.08
High
$6.30
Price Target Revisions
1 Month
38.00%
3 Months
53.33%
Price Target Summary
13 Wall Street analysts provided a forecast for the next 12 months for ALXO. The average price target is 4.69 USD. This implies a price increase of 180.96% is expected in the next year compared to the current price of 1.67.
The average price target has been revised upward by 53.33% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
81.54%
ALXO was analyzed by 13 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about ALXO.
In the previous month the buy percentage consensus was at a similar level.
ALXO was analyzed by 13 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-19 | Wells Fargo | Initiate | Overweight |
| 2026-03-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-02-05 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-05-21 | UBS | Maintains | Buy -> Buy |
| 2025-05-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-07 | Stifel | Maintains | Hold -> Hold |
| 2025-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-03-06 | Jefferies | Upgrade | Hold -> Buy |
| 2025-01-27 | UBS | Maintains | Buy -> Buy |
| 2025-01-24 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-01-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-12-19 | Jefferies | Downgrade | Buy -> Hold |
| 2024-12-18 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-12-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-08-16 | UBS | Maintains | Buy -> Buy |
| 2024-08-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-12 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-08-09 | Stifel | Reiterate | Hold -> Hold |
| 2024-08-01 | Stifel | Maintains | Hold -> Hold |
| 2024-08-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-29 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-04-12 | Cantor Fitzgerald | Reiterate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 7, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.22
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 61.31%
- Number of Analysts
- 8
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
26.67%
Next Earnings Summary
ALXO is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is -0.22 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.07M | 4.8M 131.88% | 1.18M -75.42% | -100.00% | 14.28M | 65.349M 357.63% | 155.12M 137.37% | 236.66M 52.57% | |||||||||
| EBITDA YoY % growth | -13.25M | -18.75M -41.51% | -43.46M -131.79% | -81.802M -92.15% | -137.471M -52.20% | -128.234M -33.10% | -118.85M 16.57% | -81.141M 42.51% | -103.04M -26.99% | -113.516M -10.17% | -121.666M -7.18% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -13.68M | -19.18M -40.20% | -43.66M -127.63% | -82.164M -91.39% | -136.116M -52.51% | -169.65M -33.40% | -145.484M 16.47% | -100.847M 28.98% | -90.677M 10.08% | -98.453M -8.58% | -107.158M -8.84% | -119.626M -11.63% | -116.463M 2.64% | -65.129M 44.08% | 46.516M 171.42% | 119.34M 156.56% | |
| Operating Margin | -660.87% | -399.58% | -3,700.00% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -815.57% | -99.66% | 29.99% | 50.43% | |
| EPS YoY % growth | N/A | N/A | -4.48 | -2.01 54.02% | -3.25 -47.09% | -3.51 -23.76% | -2.81 30.67% | -1.86 31.15% | -0.78 56.31% | -0.71 9.57% | -0.62 12.50% | -0.70 -13.74% | -0.58 17.39% | 8.43 1,549.12% | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.22 61.31% | -0.19 54.93% | -0.20 51.90% | -0.16 56.81% | -0.16 27.27% | -0.18 5.26% | -0.19 1.72% | -0.18 -14.89% |
| Revenue Q2Q % growth | ||||||||
| EBITDA Q2Q % growth | -24.256M 23.26% | -25.225M -9.33% | -26.245M -19.42% | -27.316M -22.41% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -23.978M 24.65% | -24.794M -5.63% | -25.597M -13.60% | -26.932M -16.99% | -22.34M 6.83% | -23.175M 6.53% | -24.273M 5.17% | -25.324M 5.97% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
18.27%
EPS Next 5 Year
10.87%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
6.85%
EBIT Next 5 Year
3.86%
ALX ONCOLOGY HOLDINGS INC / ALXO Forecast FAQ
Can you provide the upcoming earnings date for ALX ONCOLOGY HOLDINGS INC?
ALX ONCOLOGY HOLDINGS INC (ALXO) will report earnings on 2026-05-07.
Can you provide the consensus estimates for ALX ONCOLOGY HOLDINGS INC next earnings?
The consensus EPS estimate for the next earnings of ALX ONCOLOGY HOLDINGS INC (ALXO) is -0.22 USD and the consensus revenue estimate is 0 USD.
How do analysts rate ALX ONCOLOGY HOLDINGS INC (ALXO)?
The consensus rating for ALX ONCOLOGY HOLDINGS INC (ALXO) is 81.5385 / 100 . This indicates that analysts generally have a positive outlook on the stock.